CSI Market
Sign In | Register

Pharming Group N v (PHAR) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access PHAR Annual Balance Sheets →
Balance sheet patterns shown here provide context for understanding Pharming Group N v's financial stability and long-term positioning.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
0 0 0 (Dec 31 2024)
Assets
Cash And Cash Equivalents145.31
Cash & Short-term Investments145.00
Accounts receivable41.77
Inventories64.90
Other Current Assets0.00
Total Current Assets299.47
Equipment/Property/Plant Net7.23
Intangible Assets135.54
Tax Assets, Noncurrent41.50
Other Assets, Noncurrent63.72
Total Assets499.96
Liabilities
Accounts Payable105.90
Other Liabilities, Current115.79
Total Current Liabilities115.79
Total Long-term Debt0.00
Accrued Income Taxes, Noncurrent10.48
Total Liabilities222.86
Stockholders' Equity
Other Equity277.42
Common Stockholder's Equity277.42
Total Stockholder's Equity277.10
Liabilities & Stockholder's Equity499.96
4 historic quarters locked

Sign in to unlock the full Pharming Group N v balance sheet history.

Sign In Create Free Account

About Pharming Group N V Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 20-F filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001828316-26-000015

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.